TargetBeta
TNFRSF9
TNF receptor superfamily member 9 · also CD137, 4-1BB, ILA · CD molecules
14 programs in company-led studies act on TNFRSF9, from 12 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (10 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Neuroendocrine, 2 programs
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Colorectal Neoplasms, 2 programs
- Melanoma, 2 programs
- Neoplasm Metastasis, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Ovarian Epithelial, 1 program
- Carcinoma, Renal Cell, 1 program
- Endometrial Neoplasms, 1 program
- Lung Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Anti-PD-L1/4-1BB Bispecific Antibody LBL-024 · Nanjing Leads Biolabs · phase 3 · NCT05170958
- Mar 31, 2027Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033 · BeOne Medicines · phase 3 · NCT06427941
- Jul 30, 2027acasunlimab · Genmab · phase 3 · NCT06635824
- Oct 30, 2027Anti-CD137/PD-L1 Bispecific Antibody FS222 · Sino Biopharmaceutical · phase 1 · NCT04740424
- Dec 1, 2027Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015 · Medigene · phase 1 · NCT06748872
- Dec 2, 2027Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103 · ABL Bio · phase 2 · NCT07158918
- Jan 2028Allogeneic iPSC-derived CD58KO Anti-MICA/MICB CAR-ADR-expressing T-cells FT836 · Fate Therapeutics · phase 1 · NCT07216105
- May 21, 2028Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 · Sino Biopharmaceutical · phase 2 · NCT07387081
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.